Lung cancer

32 public biotech companies we cover are developing treatments for non-small cell and small cell lung cancer and mesothelioma. 15 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

Actinium Pharmaceuticals (ATNM)Thesis Challenged
Non-small cell lung cancer
Allarity Therapeutics (ALLR)Thesis Intact
Small cell lung cancer
ArriVent BioPharma (AVBP)Thesis Challenged
Non-small cell lung cancer
Black Diamond Therapeutics (BDTX)Thesis Intact
Non-small cell lung cancer
BridgeBio Oncology Therapeutics (BBOT)Thesis Intact
KRAS G12C mutant NSCLC, Non-small cell lung cancer
C4 Therapeutics (CCCC)Thesis Intact
Non-small cell lung cancer
Calidi Biotherapeutics (CLDI)Thesis Challenged
Non-small cell lung cancer
Candel Therapeutics (CADL)Thesis Intact
Lung cancer, Non-small cell lung cancer
Cardiff Oncology (CRDF)Thesis Challenged
Small cell lung cancer
Compass Therapeutics (CMPX)Thesis Challenged
Solid tumors (NSCLC), Non-small cell lung cancer
Cullinan Therapeutics (CGEM)Thesis Intact
EGFR ex20ins NSCLC, Non-small cell lung cancer
CytomX Therapeutics (CTMX)Thesis Intact
Lung cancer
Erasca (ERAS)Thesis Intact
Non-small-cell lung cancer
IDEAYA Biosciences (IDYA)Thesis Intact
Lung cancer, Small cell lung cancer, Non-small cell lung cancer
Immatics (IMTX)Thesis Intact
Squamous non-small cell lung cancer
Immuneering (IMRX)Thesis Intact
Non-small cell lung cancer
ImmunityBio (IBRX)Thesis Intact
Non-small cell lung cancer
Immunocore (IMCR)Thesis Intact
Non-small cell lung cancer
Immutep (IMMP)Thesis Challenged
Non-small cell lung cancer
Iovance Biotherapeutics (IOVA)Thesis Intact
Non-small cell lung cancer
MAIA Biotechnology (MAIA)Thesis Challenged
Non-small cell lung cancer
Nektar Therapeutics (NKTR)Thesis Intact
Non-small cell lung cancer
NovoCure (NVCR)Thesis Challenged
Non-small cell lung cancer, Malignant pleural mesothelioma, Brain metastases from non-small cell lung cancer
Nuvectis Pharma (NVCT)Thesis Intact
Non-small cell lung cancer
ORIC Pharmaceuticals (ORIC)Thesis Intact
Non-small cell lung cancer
Personalis (PSNL)Thesis Intact
Non-small cell lung cancer
Perspective Therapeutics (CATX)Thesis Intact
Non-small cell lung cancer
Pliant Therapeutics (PLRX)Thesis Intact
Non-small cell lung cancer
SELLAS Life Sciences Group (SLS)Thesis Intact
Malignant pleural mesothelioma
Summit Therapeutics (SMMT)Thesis Challenged
Non-small cell lung cancer
Tango Therapeutics (TNGX)Thesis Intact
Non-small cell lung cancer
Verastem (VSTM)Thesis Intact
Non-small cell lung cancer

Drug pages

Ivonescimab ANKTIVA (nogapendekin alfa inbakicept)Zipalertinib Lifileucel

Upcoming catalysts

Firm dates · a specific day set by the company or regulator

Next 30 days

Nov 14
in 20 days
Ivonescimab · FDA decision · Non-small cell lung cancer · EGFRm+ · second-line or later
Summit Therapeutics (SMMT)·Source

Later

Feb 27
in 125 days
Zipalertinib · FDA decision · EGFR ex20ins NSCLC · relapsed
Cullinan Therapeutics (CGEM)·Source

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in Q4 2026

Q4 2026
CTX-8371 · Phase 1 results · Solid tumors (NSCLC · TNBC · HL)
Compass Therapeutics (CMPX)·Source
Q4 2026
FDA decision on Optune Lua PMA for NSCLC brain metastases
NovoCure (NVCR)·Source

Expected in H2 2026

H2 2026
IDE849 · Phase 1 start · Extensive-stage small cell lung cancer
IDEAYA Biosciences (IDYA)·Source
H2 2026
Atebimetinib · Phase 2 start · Non-small cell lung cancer · advanced
Immuneering (IMRX)·Source
H2 2026
Ivonescimab · Phase 3 results (HARMONi-3) · Non-small cell lung cancer · first-line · squamous
Summit Therapeutics (SMMT)·Source

Expected by end of 2026

Year-end 2026
Zipalertinib · NDA submission · EGFR ex20ins NSCLC · first-line
Cullinan Therapeutics (CGEM)·Source
By end of 2026
CLD-401 · IND submission · NSCLC · head and neck cancer
Calidi Biotherapeutics (CLDI)·Source
End of 2026
NXP900 · Phase 1b interim results · Non-small cell lung cancer · EGFR-mutant, after osimertinib
Nuvectis Pharma (NVCT)·Source

Expected in Q1 2027

Q1 2027
CLD-401 · Phase 1 start · NSCLC · head and neck cancer
Calidi Biotherapeutics (CLDI)·Source

Expected in H1 2027

H1 2027
ERAS-0015 · Phase 3 start · Non-small-cell lung cancer · 2L+
Erasca (ERAS)·Source
1H 2027
Enozertinib · Phase 3 start (Redwood-1) · Non-small cell lung cancer · EGFR atypical, first-line
ORIC Pharmaceuticals (ORIC)·Source
H1 2027
Ivonescimab · Phase 3 results (HARMONi-3) · Non-small cell lung cancer · first-line · non-squamous
Summit Therapeutics (SMMT)·Source

Expected by end of June 2027

mid-2027
BBO-8520 · Phase 1 results (ONKORAS-101) · KRAS G12C mutant NSCLC · previously treated
BridgeBio Oncology Therapeutics (BBOT)·Source